Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibition (ICI) improves survival outcomes for patients with several types of cancer including metastatic melanoma (MM), but serious immune-related adverse events requiring intervention with immunosuppressive medications occur in a subset of patients. Skin toxicity (ST) has been reported to be associated with better response to ICI. However, understudied factors, such as ST severity and potential survivor bias, may influence the strength of these observed associations.

Methods

To examine the potential confounding impact of such variables, we analyzed advanced cancer patients enrolled prospectively in a clinicopathological database with protocol-driven follow up and treated with ICI. We tested the associations between developing ST, stratified as

SUBMITTER: Gulati N 

PROVIDER: S-EPMC7659132 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature